I became holder when they announced the last CR. Been a huge fan of the peptide library and traded PYC for a profit before. But I converted to a long term holder based on the likelihood of success as I see it in thd oncology space.
I simply can't say enough how groundbreaking this work is. You are fully entitled to your opinion but to characterize their work as a uni study group is derision in my view
Drug development is complex, time consuming and costly. ASX life sciences companies don't do themselves huge favours in terms of disclosure track record either.
Anyway, I see a winner in PYC. Something that can eclipse BNO as a ASX life sciences peer and draws parralels with SRX and Biota . Big call I know, but I don't make it so easily.
I see potential for the price to go to 10c in 2017 under my optimism case.
No point buying ASX listed life sciences names if you want a dividend.
PYC Price at posting:
1.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)